menu
    • menu
    [{"orgOrder":0,"company":"Polpharma Biologics","sponsor":"MS Pharma","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"POLAND","productType":"Large molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Ranibizumab","moa":"VEGFA","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Polpharma Biologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Polpharma Biologics \/ MS Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Polpharma Biologics \/ MS Pharma"},{"orgOrder":0,"company":"Polpharma Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"POLAND","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Ranibizumab","moa":"VEGFR A","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Polpharma Biologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Polpharma Biologics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Polpharma Biologics \/ Not Applicable"},{"orgOrder":0,"company":"Polpharma Biologics","sponsor":"Sandoz B2B","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"POLAND","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Natalizumab","moa":"Integrin alpha-4\/beta-1","graph1":"Neurology","graph2":"Phase III","graph3":"Polpharma Biologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous injection","sponsorNew":"Polpharma Biologics \/ Sandoz","highestDevelopmentStatusID":"10","companyTruncated":"Polpharma Biologics \/ Sandoz"},{"orgOrder":0,"company":"Polpharma Biologics","sponsor":"Sandoz B2B","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"POLAND","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Natalizumab","moa":"Integrin alpha-4\/beta-1","graph1":"Neurology","graph2":"Phase III","graph3":"Polpharma Biologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous injection","sponsorNew":"Polpharma Biologics \/ Sandoz","highestDevelopmentStatusID":"10","companyTruncated":"Polpharma Biologics \/ Sandoz"},{"orgOrder":0,"company":"Polpharma Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"POLAND","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Ranibizumab","moa":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Polpharma Biologics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Polpharma Biologics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Polpharma Biologics \/ Not Applicable"},{"orgOrder":0,"company":"Polpharma Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"POLAND","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Natalizumab","moa":"","graph1":"Neurology","graph2":"Phase III","graph3":"Polpharma Biologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Polpharma Biologics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Polpharma Biologics \/ Not Applicable"},{"orgOrder":0,"company":"Polpharma Biologics","sponsor":"Sandoz B2B","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Natalizumab-sztn","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Polpharma Biologics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Polpharma Biologics \/ Polpharma Biologics","highestDevelopmentStatusID":"12","companyTruncated":"Polpharma Biologics \/ Polpharma Biologics"},{"orgOrder":0,"company":"Polpharma Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"POLAND","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Vedolizumab","moa":"","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Polpharma Biologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Polpharma Biologics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Polpharma Biologics \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Polpharma Biologics

    Menu

    Polpharma Biologics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Polpharma Biologics

                            Poland arrow
                            PharmaVenue
                            Not Confirmed

                            Polpharma Biologics

                            Poland arrow
                            PharmaVenue
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Vedolizumab

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Polpharma's Investigational Biosimilar Shows PK/PD Comparability To Entyvio® For IBD

                            Details : PB016 (vedolizumab) is a humanized monoclonal antibody that specifically binds to the α4β7 integrin & blocks the interaction of α4β7 integrin. It is being evaluated for Ulcerative Colitis.

                            Brand Name : PB016

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            February 21, 2024

                            Lead Product(s) : Vedolizumab

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Polpharma Biologics

                            Poland arrow
                            PharmaVenue
                            Not Confirmed

                            Polpharma Biologics

                            Poland arrow
                            PharmaVenue
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Natalizumab-sztn

                            Therapeutic Area : Neurology

                            Study Phase : Approved

                            Recipient : Sandoz B2B

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Sandoz Receives FDA Approval for Tyruko (natalizumab-sztn), First and Only FDA-Approved Biosimilar for Relapsi...

                            Details : Tyruko (natalizumab-sztn) biosimilar is mAB that acts as α4 integrin antagonist to prevent leukocyte trafficking into central nervous system, demonstrated high efficacy in Phase III trials by reducing annualized relapse rate, preventing multiple scleros...

                            Brand Name : Tyruko

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            August 25, 2023

                            Lead Product(s) : Natalizumab-sztn

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved

                            Recipient : Sandoz B2B

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Polpharma Biologics

                            Poland arrow
                            PharmaVenue
                            Not Confirmed

                            Polpharma Biologics

                            Poland arrow
                            PharmaVenue
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ranibizumab

                            Therapeutic Area : Ophthalmology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            U.S. Food and Drug Administration (FDA) Approves FYB201/CIMERLITM* (ranibizumab-eqrn), The First and Only Bios...

                            Details : CIMERLI (Ranibizumab) is the first and only interchangeable biosimilar with an exclusivity for 12 months after market launch that is indicated for the treatment of all five Lucentis® indications and, as such, is a new medical option for patients with se...

                            Brand Name : Cimerli

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            August 03, 2022

                            Lead Product(s) : Ranibizumab

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Polpharma Biologics

                            Poland arrow
                            PharmaVenue
                            Not Confirmed

                            Polpharma Biologics

                            Poland arrow
                            PharmaVenue
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Natalizumab

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Polpharma Biologics Announces FDA File Acceptance For Review Of Natalizumab, First Proposed Biosimilar To Tysa...

                            Details : Tysabri® (natalizumab) - a monotherapy for adult patients with relapsing-remitting multiple sclerosis (RRMS) and adults with moderately-to-severely active Crohn’s disease.

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            July 29, 2022

                            Lead Product(s) : Natalizumab

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Polpharma Biologics

                            Poland arrow
                            PharmaVenue
                            Not Confirmed

                            Polpharma Biologics

                            Poland arrow
                            PharmaVenue
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Natalizumab

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Sponsor : Sandoz B2B

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Applications for Proposed First-of-a-kind Multiple Sclerosis Biosimilar Natalizumab Accepted by US FDA and EMA

                            Details : PB006 (natalizumab) is mAB that acts as α4 integrin antagonist to prevent leukocyte trafficking into central nervous system, demonstrated high efficacy in Phase III trials by reducing annualized relapse rate, preventing multiple sclerosis lesion accumul...

                            Brand Name : PB006

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            July 25, 2022

                            Lead Product(s) : Natalizumab

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Sponsor : Sandoz B2B

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Polpharma Biologics

                            Poland arrow
                            PharmaVenue
                            Not Confirmed

                            Polpharma Biologics

                            Poland arrow
                            PharmaVenue
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Natalizumab

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Sponsor : Sandoz B2B

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Polpharma Biologics Announces EMA Acceptance of Marketing Authorization Application for Proposed Biosimilar Na...

                            Details : Natalizumab a proposed biosimilar to Tysabri is a humanised monoclonal antibody that blocks integrin α4β1-mediated leukocyte migration from blood vessels to the brain and prevent highly active relapsing-remitting multiple sclerosis.

                            Brand Name : PB006

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            July 14, 2022

                            Lead Product(s) : Natalizumab

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Sponsor : Sandoz B2B

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Polpharma Biologics

                            Poland arrow
                            PharmaVenue
                            Not Confirmed

                            Polpharma Biologics

                            Poland arrow
                            PharmaVenue
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ranibizumab

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase III

                            Sponsor : MS Pharma

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Bioeq, the Polpharma Biologics Group Joint Venture Company and MS Pharma Sign Exclusive Agreement for Ranibizu...

                            Details : Under the exclusive agreement, MS Pharma will be responsible for the registration and commercialization of FYB201/CHS-201 (Ranibizumab), in the Middle East and North African countries. MS Pharma will start the registration procedures in MENA immediately.

                            Brand Name : CHS-201

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            December 14, 2021

                            Lead Product(s) : Ranibizumab

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase III

                            Sponsor : MS Pharma

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Polpharma Biologics

                            Poland arrow
                            PharmaVenue
                            Not Confirmed

                            Polpharma Biologics

                            Poland arrow
                            PharmaVenue
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ranibizumab

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Polpharma Biologics Group Announces that Its Joint Venture Bioeq Has Submitted a Biologics License Application...

                            Details : CHS-201 (ranibizumab), trade name Lucentis® among others is a monoclonal anti-angiogenic antibody fragment (Fab) that has been approved to treat the "wet" type of age-related macular degeneration a common form of age-related vision loss.

                            Brand Name : CHS-201

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            August 06, 2021

                            Lead Product(s) : Ranibizumab

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth